Hidden changes to prespecified primary outcomes of clinical trials completed between 2009 and 2017 in German University Medical Centres: A meta-research study
Holst, M.; Haslberger, M.; Yerunkar, S.; Strech, D.; Hemkens, L. G.; Carlisle, B. G.
Show abstract
ObjectivesTo assess how often clinical trials exhibit primary outcome discrepancies within registry records that would not be caught by comparing results publications to the latest registry entry, but would require analysing the registration history. DesignMeta-research study. SettingAll 1746 randomised clinical trials with published results, registered in ClinicalTrials.gov or Deutsches Register Klinischer Studien (DRKS), completed at German University Medical Centres between 2009 and 2017. We analysed registry entries for all trials and publications for a random sample of 292 trials. ParticipantsNot applicable. InterventionsNot applicable. Main outcome measures[1] Primary outcome discrepancies between registry entries at key study milestones and [2] the first results publication. [3] Hidden discrepancies, i.e., only reported in the registry before the last entry, meaning they would only be detected by assessing the full registry change history. We considered discrepancies major if primary outcomes were newly added, dropped, or changed to or from secondary outcomes. [4] Proportion of publications transparently reporting discrepancies. [5] Characteristics associated with open and hidden discrepancies. ResultsOf all 1746 trials, 23% (n=393) had primary outcome discrepancies between trial start and latest registry entry, with 8% (n=142) being major. Primary outcomes in publications were different from the latest registry entry in 41% of trials (120 of the 292 sampled trials; 95% CI [35%, 47%]), with major discrepancies in 18% (54 of 292; 95% CI [14%, 23%]). Hidden discrepancies were observed in 14% of trials (41/292; 95% CI [10%, 19%]). Only 1% of discrepancies were reported in the publications (2/161, 95% CI [0%, 4%]). Trials were more likely to have a within-registry discrepancy if they had an earlier registration year (OR 0.74; 95% CI [0.69, 0.80]), were registered on ClinicalTrials.gov (OR 0.41; 95% CI [0.23, 0.70]), or had been industry-sponsored (OR 0.29; 95% CI [0.21, 0.41]). ConclusionsChanges to primary trial outcomes are common, often have major relevance, are rarely transparently reported and typically not detectable with an inspection of the latest registry entry. Authors need to be more transparent and registry entries of published trials need to require more in-depth analysis to reveal potentially misleading reporting practices. Protocol registrationOpen Science Framework (https://osf.io/t3qva; amendment in https://osf.io/qtd2b).
Matching journals
The top 4 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Results reporting for clinical trials led by medical universities and university hospitals in the Nordic countries was often missing or delayed 99%
- Results dissemination from clinical trials conducted at German university medical centres was delayed and incomplete 98%
- The use of the Registered Reports format for publication of randomized clinical trials: a cross-sectional study 97%
Similar papers in this journal
- Exploring scalable assessment methods for terminated trials in ClinicalTrials.gov: A cohort analysis of German and Californian trials 97%
- How Informative Were Early SARS-CoV-2 Treatment and Prevention Trials? A longitudinal cohort analysis of trials registered on clinicaltrials.gov 96%
- Analysis of clinical trial registry entry histories using the novel R package cthist 94%
Similar papers in this journal
Similar papers in this journal
- Investigator-initiated versus industry-sponsored trials – Visibility and relevance of randomized controlled trials in clinical practice guidelines (IMPACT) 97%
- Improving research transparency with individualized report cards: A feasibility study in clinical trials at a large university medical center 96%
- Approaches in Analyzing Predictors of Trial Failure: A Scoping Review and Meta-epidemiological study 95%
Similar papers in this journal
- Transparency and reporting characteristics of COVID-19 randomized controlled trials 98%
- Tool to assess risk of bias due to missing evidence in network meta-analysis (ROB-MEN): elaboration and examples 94%
- Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.